[{"orgOrder":0,"company":"University of North Carolina","sponsor":"Wake Forest University Health Sciences | Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"University of North Carolina \/ Wake Forest University Health Sciences | Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ Wake Forest University Health Sciences | Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Intech Biopharm Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Intech Biopharm Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Wellbeing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum","moa":"Dopamine receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Green Cross Wellbeing","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Cross Wellbeing \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Green Cross Wellbeing \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Peking University | Shanghai Huilun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sivelestat Sodium Hydrate","moa":"ELANE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peking Union Medical College Hospital \/ Peking University | Shanghai Huilun Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Peking Union Medical College Hospital \/ Peking University | Shanghai Huilun Pharmaceutical"},{"orgOrder":0,"company":"Anesthesia Research Group UA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UKRAINE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Anesthesia Research Group UA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anesthesia Research Group UA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Anesthesia Research Group UA \/ Undisclosed"},{"orgOrder":0,"company":"ShiYue Li","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"ShiYue Li","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ShiYue Li \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"ShiYue Li \/ AstraZeneca"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"CSHL","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Lonodelestat","moa":"Human neutrophil elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santhera Pharmaceuticals \/ CSHL","highestDevelopmentStatusID":"1","companyTruncated":"Santhera Pharmaceuticals \/ CSHL"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez | Hospital Angeles del Pedregal","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez | Hospital Angeles del Pedregal","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez | Hospital Angeles del Pedregal"},{"orgOrder":0,"company":"ResBiotic Nutrition, Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"ResBiotic Nutrition, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ResBiotic Nutrition, Inc. \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"ResBiotic Nutrition, Inc. \/ Nutrasource"},{"orgOrder":0,"company":"ResBiotic Nutrition, Inc.","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"ResBiotic Nutrition, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ResBiotic Nutrition, Inc. \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"ResBiotic Nutrition, Inc. \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"University of St Andrews","sponsor":"ILC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Human Alpha Interferon","moa":"INF-alpha-14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of St Andrews","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of St Andrews \/ ILC Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of St Andrews \/ ILC Therapeutics"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methacholine Chloride","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Institute of Respiratory Disease","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Guangzhou Institute of Respiratory Disease","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Guangzhou Institute of Respiratory Disease \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Guangzhou Institute of Respiratory Disease \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Bispebjerg Hospital | Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health"},{"orgOrder":0,"company":"Tharimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Tharimmune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Tharimmune \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tharimmune \/ Undisclosed"},{"orgOrder":0,"company":"Nagoya University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Nagoya University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nagoya University \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Nagoya University \/ Merck & Co"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Third Pole Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Third Pole Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Third Pole Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Third Pole Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fernando Suarez Sipmann","sponsor":"Air Liquide Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Fernando Suarez Sipmann","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fernando Suarez Sipmann \/ Air Liquide Group","highestDevelopmentStatusID":"1","companyTruncated":"Fernando Suarez Sipmann \/ Air Liquide Group"},{"orgOrder":0,"company":"Gabi SmartCare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitrogen","moa":"Soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Gabi SmartCare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabi SmartCare \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Gabi SmartCare \/ Undisclosed"},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Edesa Biotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"NI-0101","moa":"Toll-like receptor 4 (TLR4)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Light Chain Bioscience","amount2":0.37,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.37,"dosageForm":"Undisclosed","sponsorNew":"Light Chain Bioscience \/ Edesa Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Light Chain Bioscience \/ Edesa Biotech"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ampio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"Oslo University Hospital | ImmunoPharma AS","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Andosan","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Akershus University Hospital \/ Oslo University Hospital | ImmunoPharma AS","highestDevelopmentStatusID":"1","companyTruncated":"Akershus University Hospital \/ Oslo University Hospital | ImmunoPharma AS"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Ap Green Tea Extract","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"Neopharm Bulgaria Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BULGARIA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Atusin Cap","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Neopharm Bulgaria Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neopharm Bulgaria Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Neopharm Bulgaria Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Probiotical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bifiasthm","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Probiotical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probiotical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Probiotical \/ Undisclosed"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"BXT-25","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioxytran \/ Undisclosed"},{"orgOrder":0,"company":"Hofseth Biocare ASA","sponsor":"M\u00f8re og Romsdal Hospital Trust","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Cardio","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Hofseth Biocare ASA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hofseth Biocare ASA \/ M\u00f8re og Romsdal Hospital Trust","highestDevelopmentStatusID":"1","companyTruncated":"Hofseth Biocare ASA \/ M\u00f8re og Romsdal Hospital Trust"},{"orgOrder":0,"company":"Hofseth Biocare ASA","sponsor":"Trondheim University Hospital | Helse More and Romsdal Trust","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Cardio","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Hofseth Biocare ASA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hofseth Biocare ASA \/ Trondheim University Hospital | Helse More and Romsdal Trust","highestDevelopmentStatusID":"1","companyTruncated":"Hofseth Biocare ASA \/ Trondheim University Hospital | Helse More and Romsdal Trust"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Cocktail","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Undisclosed"},{"orgOrder":0,"company":"Cargill","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Epicor","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Cargill","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Cargill \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Cargill \/ KGK Science"},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Fibroblast Cell","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"FibroGenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGenesis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"FibroGenesis \/ Undisclosed"},{"orgOrder":0,"company":"Arafarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Food Supplement","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Arafarma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arafarma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Arafarma \/ Undisclosed"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Hanoi Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Livespo Navax","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Hanoi Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Hanoi Medical University"},{"orgOrder":0,"company":"Innowage Limited","sponsor":"Mettle Networks | Gyansanjeevani India","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Lung Care Solution","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Innowage Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Innowage Limited \/ Mettle Networks | Gyansanjeevani India","highestDevelopmentStatusID":"1","companyTruncated":"Innowage Limited \/ Mettle Networks | Gyansanjeevani India"},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Qu Yiqing","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Ntaphylococcus Albicans","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Qu Yiqing","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qu Yiqing \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Qu Yiqing \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Sun Ten Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TAIWAN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Respireaid","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Sun Ten Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Sun Ten Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sun Ten Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Henan University of Traditional Chinese Medicine","sponsor":"Qingdao Municipal Hospital of Traditional Chinese Medicine | Henan Lingrui Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Shu Fei Tie","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Henan University of Traditional Chinese Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Henan University of Traditional Chinese Medicine \/ Qingdao Municipal Hospital of Traditional Chinese Medicine | Henan Lingrui Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Henan University of Traditional Chinese Medicine \/ Qingdao Municipal Hospital of Traditional Chinese Medicine | Henan Lingrui Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"CF PharmTech","sponsor":"Biotrack Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Series F Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CF PharmTech","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.050000000000000003,"dosageForm":"Aerosol","sponsorNew":"CF PharmTech \/ Biotrack Capital","highestDevelopmentStatusID":"1","companyTruncated":"CF PharmTech \/ Biotrack Capital"},{"orgOrder":0,"company":"McMaster University","sponsor":"Hamilton Academic Health Sciences Organization | St. Joseph's Healthcare Hamilton | Hamilton Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Hamilton Academic Health Sciences Organization | St. Joseph's Healthcare Hamilton | Hamilton Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Hamilton Academic Health Sciences Organization | St. Joseph's Healthcare Hamilton | Hamilton Health Sciences"},{"orgOrder":0,"company":"AeroRx","sponsor":"HCmed Innovations","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"AeroRx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AeroRx \/ HCmed Innovations","highestDevelopmentStatusID":"1","companyTruncated":"AeroRx \/ HCmed Innovations"},{"orgOrder":0,"company":"Koneksa Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Koneksa Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Koneksa Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Koneksa Health \/ Undisclosed"},{"orgOrder":0,"company":"GID BIO","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"GID BIO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GID BIO \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"1","companyTruncated":"GID BIO \/ Richard King Mellon Foundation"},{"orgOrder":0,"company":"Resbiotic","sponsor":"Timberline Holdings","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Resbiotic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Resbiotic \/ Timberline Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Resbiotic \/ Timberline Holdings"},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ CSL Behring"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SMSbiotech","sponsor":"USAMRICD","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"SMSbiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SMSbiotech \/ USAMRICD","highestDevelopmentStatusID":"1","companyTruncated":"SMSbiotech \/ USAMRICD"},{"orgOrder":0,"company":"CAGE Bio","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CAGE Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAGE Bio \/ Mayo Clinic","highestDevelopmentStatusID":"1","companyTruncated":"CAGE Bio \/ Mayo Clinic"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pharmaxis \/ Aptar Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Pharmaxis \/ Aptar Pharma"},{"orgOrder":0,"company":"Physio-Assist","sponsor":"Medical University of Lodz | University Hospital Krakow","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Physio-Assist","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Physio-Assist \/ Medical University of Lodz | University Hospital Krakow","highestDevelopmentStatusID":"1","companyTruncated":"Physio-Assist \/ Medical University of Lodz | University Hospital Krakow"},{"orgOrder":0,"company":"Adalvo","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"MALTA","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ Zentiva"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Paclitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Airway Obstruction.
Details :
The collaboration will combine Mayo Clinic's clinical expertise with CAGE Bio's proprietary ionic liquid technology to accelerate development of new treatment options.
Details :
Under theagreement, SMSbiotech and USAMRICD will conduct joint research focused on evaluating the efficacy of SMS cells in mitigating sulfur mustard-induced pulmonary morbidities.
Details :
Lung Care Solution is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Respiration Disorders.
Details :
Shu Fei Tie is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Details :
Molgramostim is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Pulmonary Alveolar Proteinosis, Acquired.
Details :
Gefapixant is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Chronic Cough.
Details :
Sivelestat sodium is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Respiratory Distress Syndrome.
Reset All
